you us. thank joining Thanks, and for afternoon, everyone, Deb. Good
Our Omnipod our execution growth, of by XX%. business. team results across total driven reflect by growth XX% global momentum quarter delivered outstanding Insulet and our We revenue third
achieved ongoing the provides our pandemic, model, market related near disruption. thanks from headwinds end growth experiencing was high are impact strong that to the which competitive revenue We global to of we differentiator insulation While these expectations. results, the a our is annuity of
We continue quarter another to celebrated the and record-setting in additions, new we United States. strong achieve customer
seeing this We continue over more from and COVID internationally are impact short to term. expect the
of this remarks. also are systems us expect portion insulin preference setting type Nevertheless, factors in momentum double-digit people high-teens results top up with Wayde QX positive this diabetes, launch then, increasing these expect on We our for of Until XXXX. to exciting an seeing AID for for in to first delivery automated total his to growth in X a our Omnipod and affect we continue Omnipod, among QX X. we entering revenue elaborate line XXXX. of for year, system, will including with low-XX%
X and Our team advancement prevalent, remarkable is mark a strong will this the not time type tremendous our only Diabetes job also market, in has and XXXX type revenue year both, markets becoming dynamic penetration low. growth, done but navigating and priorities. pump in more another strategic is of X of the
type one-third. X of rate over believe current its we market fact, from In penetration double U.S. years coming approximately the the can
sizable penetrated automated rates, offers driven diabetes adopting market and rate the with both at people U.S. even with Pod Internationally, with We by X in low for and X X for insulin insulin-intensive therapy digits type the markets a less growth. the Additionally, see type delivery. penetration single runways room expansion. are already technology type significant accelerated
deliver an and improved We and improved continue model old disrupt to technology experience paradigm outcomes. market differentiated business with the a leading customer that
legacy X type delivers and compared pump and Omnipod of value the the in Our success to and demonstrates power MDI markets type it X therapies. the
competitive some to headwinds beyond. While without not presents in that unlock having will X near opportunities the XXXX in AID term, growth we our Omnipod begin incredible performance the a and highlights commercialized system
our expect with mission We lives differentiated to improve and exciting of growth adoption we to as diabetes. AID platform the of highly people provide advance our years
forward take will X, on of the expected this later journey to Omnipod a with Our major upcoming clearance quarter. step track remains FDA occur which
we As we recently request responses for FDA’s shared, in submitted to our information September. the additional
the product living we pleased that diabetes. to are can’t are with market, be X as confident have wait transformative to and it We of to for part people process Omnipod bring will complete a
in review our the is only been team made Omnipod great are in has progress stages the clearance strategic process. is who partner Advancing closely the toward the we We this and the a FDA, X final working quarter. of with not
volume drive with and where Omnipod today, DASH requiring type to a has insulin coverage and channel and we our living X where the for continue we U.S. position. uniquely innovation further through positioned diabetes, model. type differentiated growing Omnipod to X leadership with pharmacy solution DASH are the a have business product terrific people market, established be penetrate We proven
clinical Additionally, we we Omnipod This compelling shared impressive data amass continue to new September includes that in benefits. many supports Omnipod’s X evidence at EASD.
strategic operational on are and consumer-focused technologies Access outcomes. global diagnosed low and delivering needs innovation, addressable to global awareness and simplicity, critically market, to strong especially including deliver track year. year another and operational discretion, its of performance of advanced throughout excellence. improved many of of growing increase, will each expanding as the progress. of people diabetes speak despite and millions like driving access such both each its and quality of remain Omnipod Awareness better benefits, strategic newly awareness life financial to our we together, now imperatives, I awareness, market our outstanding Taken
complicated. addition, technology access is far to In still too
in our U.S. broken through innovative business and awareness the our down barriers have pay-as-you-go model We campaigns. through pharmacy raised direct-to-consumer
had for our empower remain business with are more require majority pharmacy who with benefits everyone. $XX however, the to the States, and out-of-pocket consumers, the on experience with We more Even diabetes less and access United both per awareness to in for to than easier order have improving provides healthier, to paying provides date, the for with channel in for many people improved lives. and the It’s access pharmacy. efforts through vast costs pleased an care. impact successes efficient month model Insulet many our opportunities improve lower In pay-as-you-go live
Additionally, were offers type well In U.S., Payers X lives strength Omnipod for turn the volume in Omnipod physicians over pharmacy the customer our numerous within new X increased prescribe the which it’s In as expanded economic our customer payers. population. in the to over easier starts and benefits increasingly new our conversions DASH as we offers covered of range, quarter, remains once type X XX%, U.S. the the the again DASH the with customer market. pharmacy. recognizing drove reflected third to the through channel. MDI are in growth XX% to the benefits growing U.S. percentage offering type the to even Omnipod new value MDI represented in and XX% of compared strong starts, that XX% to
MDI rate come people living trend as we drive whom to the Our MDI. from X continues upward with diabetes, successfully conversion of type majority adoption among
recently more of FDA affordability, of access options other to we number We Lyumjev received use addition to with provide in clearance with a in diabetes. expanding to order for ways driving for Omnipod people Lilly’s living also are In Omnipod.
pursued A flexibility in indication, DTC which component manufacturer only United We strategy awareness provide are remains obtain our of customers. States for to this the advertising. to we alternatives the pump more and our key insulin
interest increased select efforts been awareness, Our international generate enthusiastic and to new U.S. the has in The feedback highly and contributing continue our are a and the markets to positive growth. response. customer leads
users and helps MDI unmet pumpers address. efforts that needs competitive attracting base both Our are as Omnipod
Additionally, benefits primary of population. physicians our type X Omnipod with about the driving are individuals DTC from for increased this efforts as learn diabetes more care interest underserved
will early we encouraged DTC awareness core of component So, our efforts, a results. the remain by are and
transformative DASH best innovation and model is consumer-centric will another consumers. an builds mark the and X Omnipod advantages. on innovation tubeless access already else off drive the be through faster Omnipod efforts care We Omnipod is Omnipod believe unique is competitive to our first, barriers focused U.S. are Omnipod in to Omnipod breakthrough parity we channel. we a that the at end, Omnipod controller. including will experience and the and highly value costs. system smartphone start. X are this that of great pharmacy offers. forward and increased are control priced adoption. cards advanced Today, compared that deliver step a drive accessible offer X enormous on X existing the groundbreaking experience will we accelerated and handheld eliminated and confident compatible the has delivering full the X, our and on-body remain mark are a algorithm that will an will SIM that despite in upon each our To provides affordable DASH, company anything technology Pod coverage It an In we turn, diabetes in in residing needless with technology will to a with experience burdensome The and unparalleled, market and
to X Omnipod clearance. Payers our generally efforts to to securing at terms negotiate await for launch successful eagerly coverage. a including reluctant have moving clearance, we While are speed, product full prepare been coverage prior
the Omnipod excitement around given secured have already However, coverage. substantial we X,
This extension X home advanced use. of as the find years XX We to X successful this a one durable the demonstrated us sustained improved X. We data Omnipod access the old. Omnipod of start and range; impact receive of X to on long-term our improved expect know for XX and diabetes. with living shared glycemic technology at The were study Omnipod will first One we AXc; observed time pivotal maintained people a have were clearance in in hypoglycemia. presented Omnipod highly The was study incredible position reduction course by use We through of of on pivotal head launch power thrilled demonstrates data compelling for our outstanding study the wait the over cannot management, of we months This outcomes benefits ages total a clinical to Omnipod minimal over have in recent offers. insulin that highlight demonstrated marked of X-month the and X clearly data trifecta that Omnipod safety year the XXXX. new EASD. X is results
so to expect are shortly do We FDA close our two preschool age following down X submitting and to Omnipod to expanded clearance. also the indication to
for plan to continue an indication in expanded We XXXX.
our efforts future in X our The and study. a we phase we conference. share the type six-month clinical very promising, is data Omnipod feasibility X early X the and remain to of at extension advanced results type Additionally, expect
for trial expanded clearance the pivotal this with Omnipod begin X, requirements in Following FDA on indication for an patient we discussions will population.
of be benefits insulin-dependent X delivery We in the people automated to pioneers bringing are excited type with insulin living to diabetes.
largest of our study significant living with use from addition to Across DASH. Omnipod and of time low AXc results cohort Omnipod we X,XXX In diabetes X, after use demonstrated in who XX people, also days presented approximately in children, type a and for adolescents adults. X people results the decrease hypoglycemia
in AXc used. adults, insulin of For in while decrease a was also total the daily dose demonstrating XX% achieved reduction
a evidence build portfolio we the near-term also position growth. technologies long-term are we clinical required for As of in investing our for Omnipod innovations, to
diligently app, are system mobile X iOS on with both international Omnipod integrating teams working Our an version it GX. AID globalizing Libre FreeStyle Omnipod the Abbott’s to and markets, to Dexcom’s and bring our X of
We’re in continue partners CGM our and choice two offer great to customers. to with excited these collaborating time,
our the We capabilities to are significant ecosystem digital also expand Omnipod. around leveraging
the Omnipod Today, able when his caregivers. cards also Omnipod with DASH incorporation need constant and Our mean because every thanks share and being upload controller. data unique Omnipod or SIM for care the VIEW Omnipod in built cards it users connectivity every data SIM power manually VIEW to of of mean to enhances real-time insulin user CGM no X with ones. allows to remotely. customer team, data her of experience see the of cards of app to SIM data cloud-to-cloud X Omnipod and caregivers insulin loved transfer. caregivers will have real-time will was visiting
are feasibility pivotal studies built to algorithm it and continue Looking processed our excited data provides system. type already X innovate to from a the believe we study work next-generation teams at and on our extraordinary blockbuster and to platforms our science us. technology Omnipod X, on are hard with future, We data have the AID the and we’ve
expansion, are global we regions. across growing global market international attractive to turning addressable our Now, where
our Our serve. global of Omnipod we the and estimate beyond power the XX people diabetes million with increase will global across for international are people the market expansion we living million currently to throughout further unlocks world the addressable insulin-dependent markets XX
within countries we the Asia Europe, our months, seven Pacific. in XX presence last the During global expanded Middle new East and
our business new making long-term the to our further international our and The strengthen DASH markets been nature global is in contribute our growth While markets. our model, see we for our Omnipod to ongoing, work position our adding it and given Omnipod a believe great presence AID we meaningfully results system major are potential of takes through growth has bring to time markets product we to competitive progress. our X game-changing will regions. strong to multiple across growing offering driver, international
forward, Moving existing advanced number markets of our regions. a further to penetrate global expand we technology underserved opportunities to to attractive our introduce and see to presence,
with are greatly from continue know to confident we We markets and adoption growth. can throughout strong many diabetes can people we drive the assess globe we where where benefit Omnipod and
Europe, over global on the further the within medium presence growing Asia the Middle Pac expand and and to plan East is focus region. Our near-term throughout we term, our
Lastly, invest are further efficiency will of global manufacturing of production we quality. in the a highest so tens we strengthen scale. Pods and our Today, capabilities, doing to at which operations, millions our producing continue and year
Our last excellence This positions innovation our Omnipod international of mitigate the support helped chain for the manufacturing our establish partnerships driver with track years over our capabilities and global a long-term Omnipod on several pandemic transformative market expand securing of revenue supply and represents issues we launch and suppliers double-digit key competitive have of DASH, not advantage. growing The of critical. of strong for have we our global And throughout redundant while significant the important us the closing, and growth X progress revenue margin X, release In we are to is manufacturing with the expansion. how more made clearance pipeline. expertise expansion also demand has deliver investments operational to be It will to around people this upcoming for could sustainable limited just and excited be another innovation remain strategic diabetes. are living year across gross made corner, imperatives. Omnipod and each an just growth and to
Our passionate underlying well we carrying strong finishing year and our Wayde. team is hard-working the strength. into focused turn in greatest global are I’ll and beyond. call on momentum the our the And business over and to now XXXX
